Data Coordination for the AMP Autoimmune and Related (AR) Knowledge Portal

AMP 自身免疫及相关 (AR) 知识门户的数据协调

• 批准号: 10374660
• 负责人: LARA M MANGRAVITE
• 金额: $ 40.85万
• 依托单位: SAGE BIONETWORKS
• 依托单位国家: 美国
• 财政年份: 2018
• 资助国家: 美国
• 起止时间: 2018-09-30 至 2023-08-31
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/10374660
• 关键词: Alzheimer' s Disease; Area; Autoimmune; Autoimmune Diseases; Benchmarking; Biopsy; Cells; Communities; Data; Data Coordinating Center; Development; Diagnostic; Disease; Ecosystem; Evaluation; Knowledge Portal; Lupus Nephritis; Medicine; Methods; Outcome; Outcomes Research; Population; Reproducibility; Research; Research Personnel; Resource Sharing; Resources; Rheumatoid Arthritis; Systemic Lupus Erythematosus; Validation; Work; cost; design; high dimensionality; improved; kidney biopsy; multiple data sources; open data; pre-clinical; programs; public-private partnership

Project Summary/Abstract The Accelerating Medicines Partnership (AMP) program is a public private partnership started in 2014 to transform the way diagnostics and treatments are developed. Partners work together to increase the number of diagnostics and therapies while reducing the cost of development in several disease areas. The program uses an open science paradigm to support early, iterative integration of resources and evaluation of findings across multiple independent teams. In the AMP in Alzheimer’s Disease Target Discovery and Preclinical Validation project (AMP-AD) this open approach was designed to improve observations through integration of multiple data sources, to increase confidence in outcomes through transparency, reproducibility, and benchmarking of methods and to accelerate evaluation of nominated AD targets by aggregating evidence and expertise across the field. Cross-consortium activities are supported by the Data Coordination Center (DCC) led by Sage Bionetworks. Functions include resource sharing, providing analytical workspaces for researchers to perform cross-team analytical projects, and coordinated evaluation across the program of research outcomes. This supplement is designed to extend the activities of the AMP-AD DCC to support the AMP Autoimmune disorders of rheumatoid arthritis and systemic lupus erythematosus (SLE) (AMP-RA/SLE).

项目总结/摘要 加速药物合作伙伴关系（AMP）计划是一个公私合作伙伴关系，始于2004年。 2014年，改变诊断和治疗的发展方式。合作伙伴携手 增加诊断和治疗的数量，同时降低开发成本， 几个疾病领域。该计划使用开放科学范式来支持早期，迭代 整合多个独立团队的资源和评价结果。在 AMP在阿尔茨海默病中的靶点发现和临床前验证项目（AMP-AD） 设计了一种开放的方法，通过整合多种数据来改进观测 来源，通过透明度，可重复性和 对方法进行基准测试，并通过汇总 证据和专业知识。数据支持跨联盟活动 协调中心（DCC）由Sage Bionetworks领导。功能包括资源共享， 为研究人员执行跨团队分析项目提供分析工具，以及 协调评估整个研究成果计划。该补充旨在 扩展AMP-AD DCC的活性以支持AMP自身免疫性疾病， 类风湿性关节炎和系统性红斑狼疮（SLE）（AMP-RA/SLE）。